72 / 89
72
Experience with rituximab in scleroderma:
results from a 1-year, proof-of-principle study.
Rheumatology (Oxford) 2010;49:271-80.
42.
Daoussis D, Liossis SN, Tsamandas AC,
Kalogeropoulou C, Paliogianni F, Sirinian C, et
al. Effect of long-term treatment with rituximab
on pulmonary function and skin fibrosis in
patients with diffuse systemic sclerosis. Clin
Exp Rheumatol 2012;30(2 Suppl 71):S17-22.
43.
Spiera RF, Gordon JK, Mersten JN, Magro CM,
Mehta M, Wildman HF, et al. Imatinib mesylate
(Gleevec) in the treatment of diffuse cutaneous
systemic sclerosis: results of a 1-year, phase IIa,
single-arm, open-label clinical trial. Ann Rheum
Dis 2011;70:1006-9.
44.
Khanna D, Saggar R, Mayes MD, Abtin F,
Clements PJ, Maranian P, et al. A one-year,
phase I/IIa, open-label pilot trial of imatinib
mesylate in the treatment of systemic sclerosis-
associated active interstitial lung disease.
Arthritis Rheum 2011;63:3540-6.
45.
Berger RG, Featherstone GL, Raasch RH,
McCartney WH, Hadler NM. Treatment of
calcinosis universalis with low-dose warfarin.
Am J Med 1987;83:72-6.
46.
Yoshida S, Torikai K. The effects of warfarin on
calcinosis in a patient with systemic sclerosis. J
Rheumatol 1993;20:1233-5.
47.
Cukierman T, Elinav E, Korem M, Chajek-Shaul
T. Low dose warfarin treatment for calcinosis in